查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602777

前葡萄膜炎治疗药物市场：按治疗类型、分销管道划分 - 全球预测 2025-2030

Anterior Uveitis Treatment Market by Treatment Type (Anti-Tumor Necrosis Factor Agents, Corticosteroids, Cycloplegic Agents), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年前葡萄膜炎治疗药物市值为2.5563亿美元，预计到2024年将达到2.7728亿美元，复合年增长率为8.56%，到2030年将达到4亿美元。

前葡萄膜炎是一种常见的眼部发炎，会影响葡萄膜，需要以缓解疼痛、减少发炎和预防视力併发症为重点的治疗。该市场包括皮质类固醇、免疫抑制剂和新生物製药等药物疗法，以及雷射疗法和手术等非药物干预措施。患者人口统计、根本原因和疾病严重程度等变数推动了对各种治疗方法的需求，这些变数指导了它们在医院、眼科诊所和眼科保健中心的应用。全球盛行率的提高、认识的提高以及诊断技术的进步是药物配方和输送系统创新的关键成长动力和机会。特别是，生物目标的开发是解决副作用较少的精确治疗的未满足需求的一种有前景的方法。然而，市场面临药物成本高、报销政策限制和潜在副作用等挑战，这些挑战可能会抑制可及性和患者依从性。克服专利悬崖和监管障碍使市场动态更加复杂。公司应特别关註生技药品和生物相似药的研发，以充分利用其管道的未来性。投资与学术和研究机构的合作伙伴关係可以促进创新并扩大治疗选择。儘管存在这些机会，但它们需要战略思维，考虑到学名药製造商的竞争压力以及以患者为中心的护理模式的整合。市场强烈面向综合护理，需要个人化医疗方法的进步和增强的诊断工具，以更有效地识别疾病进展。为了实现永续成长，我们可以透过探索跨国企业发展并利用数位平台进行病人参与和远端医疗来开拓新的细分市场。最终，前葡萄膜炎药物领域需要灵活的策略来适应不断变化的医疗、经济和技术转变。

主要市场统计
基准年[2023] 2.5563亿美元
预测年份 [2024] 27728万美元
预测年份 [2030] 4.5431亿美元
复合年增长率（%） 8.56%

市场动态：快速发展的前葡萄膜炎治疗市场的关键市场洞察

供需的动态交互作用正在改变前葡萄膜炎药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 眼部感染疾病增加
    • 对皮质类固醇和发炎药物等药品的需求增加
    • 提高葡萄膜炎治疗意识
  • 市场限制因素
    • 药品价格高，药品认知度低
  • 市场机会
    • 生物药品研究公司的发展
    • 葡萄膜炎新药和治疗方法的研发成本增加
  • 市场挑战
    • 与皮质类固醇治疗相关的副作用

波特五力：开拓前葡萄膜炎药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对前葡萄膜炎治疗药物市场的影响

外部宏观环境因素在塑造前葡萄膜炎治疗药物市场的表现动态中发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 前视图 了解葡萄膜炎治疗药物市场的竞争状况

前葡萄膜炎治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵前葡萄膜炎治疗药物市场供应商的绩效评估

FPNV 定位矩阵是评估前葡萄膜炎治疗药物市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製前葡萄膜炎治疗药物市场的成功之路

对于希望加强在全球市场的影响力的公司来说，前葡萄膜炎治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 眼部感染疾病的发生率增加
      • 对皮质类固醇和发炎药物等药品的需求增加
      • 提高对葡萄膜炎治疗的认识
    • 抑制因素
      • 费用高，药品认知度低
    • 机会
      • 发展生物药物研究公司
      • 增加葡萄膜炎新药和治疗方法的研发支出
    • 任务
      • 与皮质类固醇治疗相关的副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依治疗类型分類的前葡萄膜炎治疗药物市场

  • 抗肿瘤坏死因子剂
  • 皮质类固醇
  • 睫状肌麻痹药
  • 免疫抑制剂

第七章前葡萄膜炎治疗药物市场：按分销管道

  • 医院药房
  • 网路药房
  • 零售药房

第八章北美和南美前葡萄膜炎治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区前葡萄膜炎治疗药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲前葡萄膜炎治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Aciont Inc.
  • Ajanta Pharma Ltd
  • Aldeyra Therapeutics, Inc.
  • Alimera Sciences Inc.
  • American Academy of Ophthalmology
  • Amgen Inc.
  • Bausch & Lomb Incorporated
  • Cipla Ltd.
  • Clearside Biomedical, Inc.
  • Enzo Biochem Inc.
  • Eyegate Pharmaceuticals, Inc
  • HanAll Biopharma
  • Kiora Pharmaceuticals, Inc.
  • LV PRASAD EYE INSTITUTE
  • Lux Biosciences, Inc.
  • Novartis AG
  • Oculis SA
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Sirion Therapeutics, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Tarsier Pharma Ltd
  • Xoma Corporation
Product Code: MRR-ED54C46E910D

The Anterior Uveitis Treatment Market was valued at USD 255.63 million in 2023, expected to reach USD 277.28 million in 2024, and is projected to grow at a CAGR of 8.56%, to USD 454.31 million by 2030.

Anterior uveitis, a common form of eye inflammation affecting the uvea, requires treatment focusing on alleviating pain, reducing inflammation, and preventing vision complications. This market encompasses pharmacologic therapies, including corticosteroids, immunosuppressive agents, and newer biologics, as well as non-pharmacologic interventions like laser therapy and surgical options. The necessity for diverse treatment modalities is driven by variables such as patient demographics, underlying causes, and disease severity, which guide its application across hospital settings, ophthalmic clinics, and specialty eye care centers. The growing global prevalence, increased awareness, and advancements in diagnostic technology are key growth drivers, presenting opportunities for innovation in drug formulation and delivery systems. Notably, the development of targeted biologic therapies offers promising avenues, addressing the unmet need for precision treatment with fewer side effects. However, the market faces challenges including high drug costs, limited reimbursement policies, and potential side effects, which can impede accessibility and patient adherence. Navigating patent cliffs and regulatory hurdles further complicates market dynamics. Companies should focus on R&D, particularly in biologics and biosimilars, to capitalize on pipeline prospects. Investing in partnerships with academic institutions and research organizations can foster innovation and expand therapeutic options. Despite these opportunities, strategic maneuvers must account for competitive pressures from generic medication manufacturers and the integration of patient-centric care models. The market shows a strong orientation toward comprehensive care, necessitating advancements in personalized medicine approaches and enhanced diagnostic tools to identify disease progression more effectively. For sustainable growth, exploring cross-border expansions and leveraging digital platforms for patient engagement and telemedicine could unlock new market segments. Ultimately, the anterior uveitis treatment landscape demands agile strategies to adapt to evolving medical, economic, and technological shifts.

KEY MARKET STATISTICS
Base Year [2023] USD 255.63 million
Estimated Year [2024] USD 277.28 million
Forecast Year [2030] USD 454.31 million
CAGR (%) 8.56%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anterior Uveitis Treatment Market

The Anterior Uveitis Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of eye infections
    • Growing demand for drugs such as corticosteroids and anti-inflammatory medications
    • Growing awareness about the uveitis treatment
  • Market Restraints
    • High cost and limited awareness about the medications
  • Market Opportunities
    • Development of research companies on biological drugs
    • Rising expenditure on the research and development of novel drugs and treatments for Uveitis
  • Market Challenges
    • Side effect associated with corticosteroid treatment

Porter's Five Forces: A Strategic Tool for Navigating the Anterior Uveitis Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anterior Uveitis Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anterior Uveitis Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anterior Uveitis Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anterior Uveitis Treatment Market

A detailed market share analysis in the Anterior Uveitis Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anterior Uveitis Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anterior Uveitis Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anterior Uveitis Treatment Market

A strategic analysis of the Anterior Uveitis Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anterior Uveitis Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Aciont Inc., Ajanta Pharma Ltd, Aldeyra Therapeutics, Inc., Alimera Sciences Inc., American Academy of Ophthalmology, Amgen Inc., Bausch & Lomb Incorporated, Cipla Ltd., Clearside Biomedical, Inc., Enzo Biochem Inc., Eyegate Pharmaceuticals, Inc, HanAll Biopharma, Kiora Pharmaceuticals, Inc., L V PRASAD EYE INSTITUTE, Lux Biosciences, Inc., Novartis AG, Oculis SA, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., Sirion Therapeutics, Inc., Sun Pharmaceutical Industries Ltd., Tarsier Pharma Ltd, and Xoma Corporation.

Market Segmentation & Coverage

This research report categorizes the Anterior Uveitis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Anti-Tumor Necrosis Factor Agents, Corticosteroids, Cycloplegic Agents, and Immunosuppressants.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of eye infections
      • 5.1.1.2. Growing demand for drugs such as corticosteroids and anti-inflammatory medications
      • 5.1.1.3. Growing awareness about the uveitis treatment
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and limited awareness about the medications
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of research companies on biological drugs
      • 5.1.3.2. Rising expenditure on the research and development of novel drugs and treatments for Uveitis
    • 5.1.4. Challenges
      • 5.1.4.1. Side effect associated with corticosteroid treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Anterior Uveitis Treatment Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Anti-Tumor Necrosis Factor Agents
  • 6.3. Corticosteroids
  • 6.4. Cycloplegic Agents
  • 6.5. Immunosuppressants

7. Anterior Uveitis Treatment Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Online Pharmacies
  • 7.4. Retail Pharmacies

8. Americas Anterior Uveitis Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Anterior Uveitis Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Anterior Uveitis Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Aciont Inc.
  • 3. Ajanta Pharma Ltd
  • 4. Aldeyra Therapeutics, Inc.
  • 5. Alimera Sciences Inc.
  • 6. American Academy of Ophthalmology
  • 7. Amgen Inc.
  • 8. Bausch & Lomb Incorporated
  • 9. Cipla Ltd.
  • 10. Clearside Biomedical, Inc.
  • 11. Enzo Biochem Inc.
  • 12. Eyegate Pharmaceuticals, Inc
  • 13. HanAll Biopharma
  • 14. Kiora Pharmaceuticals, Inc.
  • 15. L V PRASAD EYE INSTITUTE
  • 16. Lux Biosciences, Inc.
  • 17. Novartis AG
  • 18. Oculis SA
  • 19. Pfizer Inc.
  • 20. Regeneron Pharmaceuticals, Inc.
  • 21. Santen Pharmaceutical Co., Ltd.
  • 22. Sirion Therapeutics, Inc.
  • 23. Sun Pharmaceutical Industries Ltd.
  • 24. Tarsier Pharma Ltd
  • 25. Xoma Corporation

LIST OF FIGURES

  • FIGURE 1. ANTERIOR UVEITIS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. ANTERIOR UVEITIS TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTERIOR UVEITIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ANTERIOR UVEITIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. ANTERIOR UVEITIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTERIOR UVEITIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTERIOR UVEITIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTERIOR UVEITIS TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY ANTI-TUMOR NECROSIS FACTOR AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY CYCLOPLEGIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM ANTERIOR UVEITIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. ANTERIOR UVEITIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 103. ANTERIOR UVEITIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023